home / stock / lexxw / lexxw news


LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 12/20/22

Stock Information

Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com

Menu

LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...

LEXXW - Lexaria's Human Oral Nicotine Study Begins Dosing

Lexaria's DehydraTECH-nicotine pouch performance to be compared to existing leading brands ON! and Zyn KELOWNA, BC / ACCESSWIRE / December 20, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased t...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its patented DehydraTECH-CBD(TM) has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). According to the up...

LEXXW - Lexaria's DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program

KELOWNA, BC / ACCESSWIRE / November 29, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its patented DehydraTECH-CBD™ has demonstrated performance enhancements compared to one of the...

LEXXW - Lexaria's DehydraTECH-CBD Enhances Performance Compared to Epidiolex in Seizure Study Program

--News Direct-- Kelowna, British Columbia – TheNewswire - November 29, 2022 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that its patented Dehydra...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Focus on Dementia and Diabetes Featured in New Interview

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, was featured in an interview produced by PCG Digital Holdings LLC and published on NewMediaWire . John Docherty, Lexaria’s president and head of research, discussed the company’s efforts...

LEXXW - Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia

KELOWNA, BC / ACCESSWIRE / November 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DEM-A22-1 is expected to begin on November 15, 2022. This is Lexaria's first-ever study...

LEXXW - Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes

KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DIAB-A22-1 is expected to begin on schedule today. This is Lexaria's first-ever study ...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacoki...

LEXXW - Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study

Lexaria's DehydraTECH-nicotine pouch performance to be compared to existing leading brands ON! and Zyn KELOWNA, BC / ACCESSWIRE / November 1, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is ple...

LEXXW - Lexaria's Human Clinical Hypertension Study a Success

HYPER-H21-4 using DehydraTECH-CBD evidenced: Exceptional safety and tolerability Statistically significant lowering of 24-hour ambulatory blood pressure ("BP") BP lowered for the entire 5-week study duration BP lowered both for patients currently taking other antihyperte...

Previous 10 Next 10